Quantification and Kinetic Analysis of Grb2-EGFR Interaction on Micro-Patterned Surfaces for the Characterization of EGFR-Modulating Substances
暂无分享,去创建一个
Stephan M. Winkler | Julian Weghuber | Peter Lanzerstorfer | G. Schütz | Daniela Borgmann | Julian Weghuber | O. Höglinger | Peter Lanzerstorfer | Otmar Höglinger | Daniela Borgmann | Gerhard Schütz | J. Weghuber
[1] A. Sorkin,et al. Live-cell fluorescence imaging reveals high stoichiometry of Grb2 binding to the EGF receptor sustained during endocytosis , 2014, Journal of Cell Science.
[2] A. Bader,et al. Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif , 2013, Journal of Cell Science.
[3] M. Brameshuber,et al. Determination of binding curves via protein micropatterning in vitro and in living cells , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[4] Qi Wu,et al. Microplate-compatible total internal reflection fluorescence microscopy for receptor pharmacology. , 2013, Applied physics letters.
[5] Y. Yarden,et al. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR , 2013, Proceedings of the National Academy of Sciences.
[6] Jaroslaw Jacak,et al. Identification of patterns in microscopy images of biological samples using evolution strategies , 2012 .
[7] Ji Yu,et al. Fast rebinding increases dwell time of Src homology 2 (SH2)-containing proteins near the plasma membrane , 2012, Proceedings of the National Academy of Sciences.
[8] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[9] G. Schütz,et al. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. , 2012, Cardiovascular research.
[10] C. Antczak,et al. Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells. , 2012, Assay and drug development technologies.
[11] Hye-Nan Kim,et al. Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels. , 2012, International journal of oncology.
[12] P. Harari,et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.
[13] M. Brameshuber,et al. Temporal resolution of protein–protein interactions in the live-cell plasma membrane , 2010, Analytical and bioanalytical chemistry.
[14] Rainer Pepperkok,et al. In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays , 2010, Nature Methods.
[15] S. Gygi,et al. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor , 2010, The Journal of cell biology.
[16] S. Swanson,et al. Multiplexed Evaluation of a Cell-Based Assay for the Detection of Antidrug Neutralizing Antibodies to Panitumumab in Human Serum Using Automated Fluorescent Microscopy , 2010, Journal of biomolecular screening.
[17] M. Brameshuber,et al. In-vivo Detection of Protein-protein Interactions on Micro-patterned Surfaces , 2010, Journal of visualized experiments : JoVE.
[18] D. Lauffenburger,et al. Systems Analysis of EGF Receptor Signaling Dynamics with Micro-Western Arrays , 2010, Nature Methods.
[19] Gerhard J Schütz,et al. Detection of protein-protein interactions in the live cell plasma membrane by quantifying prey redistribution upon bait micropatterning. , 2010, Methods in enzymology.
[20] Xavier Duval,et al. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. , 2009, Human pathology.
[21] C. Enrich,et al. Annexins--modulators of EGF receptor signalling and trafficking. , 2009, Cellular signalling.
[22] Gerhard J Schütz,et al. Micropatterning for quantitative analysis of protein-protein interactions in living cells , 2008, Nature Methods.
[23] P. P. Di Fiore,et al. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. , 2008, Developmental cell.
[24] L. Sequist,et al. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. , 2008, Annual review of medicine.
[25] A. Sorkin,et al. Endocytosis and intracellular trafficking of ErbBs. , 2008, Experimental cell research.
[26] Hiroaki Takagi,et al. Multiple-state reactions between the epidermal growth factor receptor and Grb2 as observed by using single-molecule analysis , 2007, Proceedings of the National Academy of Sciences.
[27] Qiang Wang,et al. ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.
[28] S. Hubbard,et al. Receptor tyrosine kinases: mechanisms of activation and signaling. , 2007, Current opinion in cell biology.
[29] Erez M. Bublil,et al. The EGF receptor family : spearheading a merger of signaling and therapeutics , 2007 .
[30] M. McNiven,et al. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. , 2006, Cancer research.
[31] N. Normanno,et al. Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.
[32] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[33] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[34] D. Rouillard,et al. Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro , 2004, British Journal of Cancer.
[35] D. M. Olive,et al. Quantitative methods for the analysis of protein phosphorylation in drug development , 2004, Expert review of proteomics.
[36] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[37] J. Grandis,et al. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. , 2004, Cancer treatment reviews.
[38] Xuejun Jiang,et al. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. , 2003, Molecular biology of the cell.
[39] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[40] C. Arteaga. Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.
[41] A. Sorkin,et al. Effect of Tyrosine Kinase Inhibitors on Clathrin-coated Pit Recruitment and Internalization of Epidermal Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.
[42] J. Lippincott-Schwartz,et al. Role of Grb2 in EGF-stimulated EGFR internalization. , 2002, Journal of cell science.
[43] D. Bigner,et al. EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.
[44] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[45] J. Schlessinger,et al. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor , 1994, Molecular and cellular biology.
[46] A. Ullrich,et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.